Slingshot members are tracking this event:
Celgene (CELG) Phase III data readout of RELEVANCE trial testing Revlimid in previously untreated follicular lymphoma expected by end of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|CELG||Community voting in process|
Slingshot Insights Explained
Dec 21, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Results, Relevance, Indolent Non-hodgkin Lymphoma, Revlimid